Cite
Supplemental Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
MLA
Steven P. Balk, et al. Supplemental Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2243e754143f4ba19d602fd162f43be0&authtype=sso&custid=ns315887.
APA
Steven P. Balk, Jerome Ritz, F. Stephen Hodi, Anita Giobbie-Hurder, Glenn Dranoff, Heather Daley, Christine Canning, Kenneth LeClair, David Nemer, Justice Clark, Yo Mizukami, Wanyong Zeng, Tetsuro Sasada, Simon Yue, Lianne Vriend, Nadia Alatrakchi, Phillip Friedlander, & Mark A. Exley. (2023). Supplemental Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
Chicago
Steven P. Balk, Jerome Ritz, F. Stephen Hodi, Anita Giobbie-Hurder, Glenn Dranoff, Heather Daley, Christine Canning, et al. 2023. “Supplemental Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2243e754143f4ba19d602fd162f43be0&authtype=sso&custid=ns315887.